Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
  • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
  • A61K31/724—Cyclodextrins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
  • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
  • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Definitions

• the invention relates to development of new antibiotics against pathogenic bacteria.
• the invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance.
• This new class of antibiotics are derivatives of ⁇ -cyclodextrin ( ⁇ -CD), which is a cyclic molecule comprising seven D-glucose units.
• compositions comprise one or more members of the compounds disclosed in the invention and a pharmaceutically acceptable carrier.
• the invention provides methods for using a compound or compounds having the formula:
• R 2 is H, OH, OAc, OMe, O-lower alkyl, or 0(CH 2 CH 2 O) n ;
• R 3 is H, OH, OAc, OMe, O-lower alkyl, OSO 3 Na, orNH 2 ;
• R 6 is H, NH 2 , S(CH 2 ) m NH 2 , 1, N 3 , SH, lower alkyl, S-alkylguanidyl, O-alkylguanidyl, S-aminoalkyl, O-aminoalkyl, aminoalkyl, O- lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO 3 Na or N which is mono, di or tri- substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alky
• the invention provides a method for inhibiting the growth of a bacterium. In a further embodiment of this aspect, the invention provides methods for treating a bacterial infection. In a further embodiment of this aspect, the invention provides methods for preventing a bacterial infection.
• the invention provides methods for potentiating the activity of antibiotics to inhibit the growth of a bacterium which are resistant to clinically used antibiotics, to treat or prevent an infection by these bacteria.
• the invention relates to development of new antibiotics against pathogenic bacteria.
• the invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance.
• This new class of antibiotics are derivatives of ⁇ -cyclodextrin ( ⁇ -CD), which is a cyclic molecule comprising seven D-glucose units.
• compositions comprise one or more members of the compounds disclosed in the invention and a pharmaceutically acceptable carrier.
• carrier encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, or other material well known in the art for use in pharmaceutical formulations. It will be understood that the characteristics of the carrier, excipient, or diluent will depend on the route of administration for a particular application. The preparation of pharmaceutically acceptable formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, PA, 1990, ISBN: 0-912734-04-3.
• the invention provides methods for using a compound or compounds of the first and second aspects of the invention as antimicrobial agents.
• the invention provides a method for inhibiting the growth of a bacterium. The method according to this embodiment of the invention comprises contacting the bacteria with one or more members of a compound having the formula
• the invention provides methods for treating a bacterial infection.
• the method according to this embodiment of the invention comprises administering to a mammal with a bacterial infection one or more members of a compound having the formula
• the term “lower alkyl” means an alkyl group from 1 to 7 carbon atoms.
• the terms “alkyl” and “aryl” include alkyl or aryl groups which may be substituted or unsubstituted. Preferred substitutions include, without limitation, substitution with nitrogen containing moieties, including amino groups, which may be mono or disubstituted, preferably with alkyl or aryl groups.
• the term “alkyl” includes chains of 1-7 atoms with one or more nitrogen atoms and the remainder carbon atoms.
• the invention provides methods for preventing a bacterial infection.
• the method according to this embodiment of the invention comprises administering to a mammal susceptible to a bacterial infection one or more members of a compound having the formula
• lower alkyl means an alkyl group from 1 to 7 carbon atoms.
• alkyl and aryl include alkyl or aryl groups which may be substituted or unsubstituted. Preferred substitutions include, without limitation, substitution with nitrogen containing moieties, including amino groups, which may be mono or disubstituted, preferably with alkyl or aryl groups.
• alkyl includes chains of 1-7 atoms with one or more nitrogen atoms and the remainder carbon atoms.
• the invention provides methods for potentiating the activity of antibiotics to inhibit the growth of a bacterium which are resistant to clinically used antibiotics, to treat or prevent an infection by these bacteria.
• the methods according to this aspect of the invention comprise contacting the bacterium with said antibiotic and one or more members of a compound having the formula
• R 2 is H, OH, OAc, OMe 5 0-lower alkyl, or 0(CH 2 CH 2 O) n ;
• R 3 is H, OH, OAc, OMe, 0-lower alkyl, OSO 3 Na 5 or NH 2 ;
• R 6 is H, NH 2 , S(CH 2 ) m NH 2 , 1 5 N 3 , SH 5 lower alkyl, S-alkylguanidyl, O-alkylguanidyl, S-aminoalkyl, O-aminoalkyl, aminoalkyl, O- lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO 3 Na or N which is mono, di or tri- substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H,
• lower alkyl means an alkyl group from 1 to 7 carbon atoms.
• alkyl and aryl include alkyl or aryl groups which may be substituted or unsubstituted. Preferred substitutions include, without limitation, substitution with nitrogen containing moieties, including amino groups, which may be mono or disubstituted, preferably with alkyl or aryl groups.
• alkyl includes chains of 1-7 atoms with one or more nitrogen atoms and the remainder carbon atoms.
• potentiation may be defined as a circumstance in which a compound substantially lowers the MIC of an antibacterial agent toward one or more organisms. It includes the case in which it effectively restores the therapeutic utility of an antibacterial agent whose utility has been compromised by bacterial resistance.
• one or more members of compounds of the invention can be administered in combination with any other antibiotic useful for treating the disease or condition that does not diminish the antimicrobial effect of the compound.
• the term "in combination with” means in the course of treating the same disease in the same patient, and includes administering the compound and an antibiotic in any order, including simultaneous administration, as well as any temporally spaced order, for example, from sequentially with one immediately following the other to up to several days apart.
• Such combination treatment may also include more than a single administration of the compound, and independently the antibiotic.
• the administration of the compound and antibiotic may be by the same or different routes.
• the bacteria is in a mammal.
• the mammal is a human.
• administration of the compound can be by any suitable route, including, without limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal or vaginal.
• Administration of the therapeutic compositions can be carried out using known procedures at dosages and for periods of time effective to reduce symptoms or surrogate markers of the infection.
• a doctor can determine the appropriate dose to administer or therapeutic protocol useful for preventing or preventing a bacterial infection. It may be desirable to administer simultaneously, or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode.
• Methicillin-resistant staphylococcus aureus is a bacterial infection resistant to antibiotic methicillin and can no longer be killed by this antiobiotic.
• various compounds were used antibiotics to treat Staphylococcus aureus (Methicillin resistant). The results are shown in Table 5 below. These results below demonstrate that compounds of the invention are able to retain activity against Methicillin resistance.
• Staphylococcus aureus* susceptible
• Staphylococcus aureus Metal-resistant
• Compound MIC ⁇ g/mL Compound MIC ⁇ g/mL

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Polymers & Plastics (AREA)
• Materials Engineering (AREA)
• Biochemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (2)

Family

ID=36777776

Family Applications (1)

Country Status (12)

Cited By (5)

Families Citing this family (19)

Family Cites Families (59)

• 2006
  • 2006-01-27 CN CNA2006800101557A patent/CN101151037A/zh active Pending
  • 2006-01-27 US US11/342,339 patent/US7737132B2/en not_active Expired - Fee Related
  • 2006-01-27 MX MX2007010129A patent/MX2007010129A/es unknown
  • 2006-01-27 RU RU2007133709/04A patent/RU2007133709A/ru not_active Application Discontinuation
  • 2006-01-27 CA CA002596026A patent/CA2596026A1/en not_active Abandoned
  • 2006-01-27 JP JP2007553231A patent/JP2008528761A/ja active Pending
  • 2006-01-27 KR KR1020077019399A patent/KR20070101347A/ko not_active Withdrawn
  • 2006-01-27 AU AU2006211173A patent/AU2006211173A1/en not_active Abandoned
  • 2006-01-27 EP EP06733927A patent/EP1846006A4/en not_active Withdrawn
  • 2006-01-27 WO PCT/US2006/002801 patent/WO2006083678A2/en not_active Ceased
• 2007
  • 2007-07-26 ZA ZA200706191A patent/ZA200706191B/xx unknown
  • 2007-07-26 IL IL184844A patent/IL184844A0/en unknown
• 2010
  • 2010-05-03 US US12/772,740 patent/US20110071108A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events